This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
SHR-1314 injection
Placebo
Huashan Hospital of the Shanghai FuDan University
Shanghai, Shanghai Municipality, China
RECRUITINGProportion of subjects achieving ACR 20 improvement at week 24
Time frame: Week 24
The proportion of subjects who achieved ACR 50 improvement
Time frame: Week 24
The proportion of subjects who achieved ACR 70 improvement
Time frame: Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.